|
⚲
|
| Keyboard |
| Blackstone Life Sciences Advisors LLC
✚
|
|
|---|---|
| CRD # | 304477 |
| SEC # | 801-116920 |
| CIK # | |
| AUM | 13.19 B (2026-03-30) |
| Employees | 31 (68% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 617-949-2200 |
| Address | 314 Main Street Cambridge, MA 02142 |
| Source | [IAPD] [Website] [Twitter] [LinkedIn] [Facebook] [Instagram] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation Management Fees and Performance Fees Per the Advisory Agreements with each of the Funds, BXLS Advisors is entitled to compensation for its services in the form of a management fee (the “Management Fee”), generally payable quarterly in arrears, through the duration detailed in the applicable Organizational Documents of a Fund, including potentially through the complete liquidation of a Fund. The Management Fee is based on either committed capital or invested capital (the calculation of which can take into account different factors for different Funds: investors are encouraged to read the Organizational Documents for the applicable Fund. For example, for the BXLS Yield Funds, distributions of royalty entitlements and ongoing payments of a debt instrument will not reduce invested capital for purposes of calculating the Management Fee), depending on the Funds and whether the Funds’ investment period is currently active, as applicable. For certain Funds, BXLS Advisors agreed to waive Management Fees for a specified period of time following such Fund’s effective date with respect to limited partners and participating members in the Funds (the “Fund Investors”) that satisfied certain criteria, such as if a Fund Investor participated in an early closing of a Fund or made a commitment to a Fund above a certain threshold. Prorated refunds would be provided for partial quarters, if any, to the extent applicable. In instances where the Fund’s Management Fee is calculated (in part) based on invested capital rather than capital commitments, there would be an incentive for BXLS Advisors to defer realization of Investments, make more speculative Investments than it otherwise would have made if Management Fees were based solely on capital commitments, seek to deploy the capital commitments in Investments at an accelerated pace and/or hold Investments longer than it otherwise would have if Management Fees were based on capital commitments. As set forth in Item 6 below, the General Partners of the Funds are eligible to receive performance-based or “carried interest” allocations. The Confidential Private Placement Memoranda (as supplemented from time to time) and the partnership agreements and Advisory Agreements (collectively, the “Organizational Documents”) of each of the Funds include further details on fees and compensation and related matters. Management Fees and performance-based allocations are either withheld from distributions or, in the case of Management Fees, invoiced at an appropriate time pursuant to a capital call notice. Certain investors in the Funds, including current and/or former senior/executive/operating/or other advisors, officers, directors, and personnel of Blackstone and/or other key advisors/relationships (including operating partners, executives, founders and entrepreneurs), Portfolio Entities (as defined herein) of the Funds and “Other Blackstone Clients” (as defined herein), including the BTAS Funds, BXPE, BXMA Funds, BIS Funds and BXCI Clients (each as defined herein) and any other existing or future Other Blackstone Clients, personnel of PJT Partners Inc. (“PJT”) and/or charitable programs, endowment funds and related entities established by or associated with any of the foregoing (including any trusts, family members, family investment vehicles, estate planning vehicles, descendants, trusts and other related persons or entities), and other persons related to Blackstone (“Blackstone Investors”), will not pay Management Fees or performance-based carried interest allocations in connection with their investment in the Funds or Blackstone-sponsored investment vehicles that make investments in or alongside one or more of the Funds. For the avoidance of doubt, in the case of an affiliated Fund Investor that is an Other Blackstone Client with its own underlying investors, such underlying investors are generally subject to carried interest and/or management fees in connection with their investment in such Other Blackstone Client. Notwithstanding the foregoing, such investors will either directly pay for their pro rata share of certain Fund expenses (as described below), or the pro rata amount of such expenses will be allocated to BXLS Advisors or its affiliates. Such pro rata allocation of Fund expenses will, in certain circumstances, be calculated based on capital commitments, invested capital, available capital or other metrics as determined by BXLS Advisors or its affiliates in their sole discretion. Any such methodology (including the choice thereof) involves inherent conflicts and will, in certain circumstances, not result in perfect attribution and allocation of expenses. In addition, to the extent current and/or former partners, employees, advisers and other persons referred to above, including their charitable programs, endowment funds, and related entities established by or associated with any of the foregoing (including any trusts, family members, family investment vehicles, estate planning vehicles, descendants and other related persons or entities), make capital commitments and/or otherwise invest in or alongside the Funds, any such amounts will in certain circumstances, in Blackstone’s sole discretion, be treated as satisfying the applicable portion of any required capital commitment of Blackstone and/or its affiliates to the Funds, as applicable (even in circumstances where any such commitments or investments are made following a separation from Blackstone). For more information with respect to the allocation of the Funds’ expenses, please see “Expenses” in Item 5 below. Blackstone Strategic Relationships & Multi-Fund Arrangements In addition, Blackstone has entered, and it can be expected that Blackstone in the future will enter, into both (i) strategic relationships with investors (and/or one or more of their affiliates) that involve an overall relationship with Blackstone that could (but is not required to) incorporate ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7 – Types of Clients BXLS Advisors manages the Funds. The Funds’ investors could consist of some or all of the following: Banks and other financial institutions Insurance companies Investment companies Public and private retirement and pension plans Public and private profit-sharing plans Trusts and estates Charitable organizations and foundations, including endowment funds thereof State and municipal government agencies Sovereign wealth funds Private investment funds Corporations Business entities other than those listed above High net worth individuals Family offices Investors also include other funds, vehicles and/or accounts managed by affiliates of Blackstone (including investors in Funds established for the BTAS Funds, Blackstone Harrington Partners L.P, Blackstone Holdings Partners (Cayman) L.P., Blackstone Credit and Insurance Funds (“BXCI Clients”), BXPE, BXMA Funds and Strategic Partners funds). All investors are subject to applicable suitability requirements. BXLS Advisors and each General Partner require that each investor in the Funds be (i) an “accredited investor” as defined in Regulation D under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and (ii) a “qualified purchaser” as defined in Section 2(a)(51) of the U.S. Investment Company Act of 1940, as amended (the “1940 Act”), and/or meet other suitability requirements (including, in some circumstances, a person that is not a U.S. Person as defined in Regulation S under the Securities Act). Generally, investors must invest a minimum dollar amount as determined in the applicable General Partner’s sole discretion. Each General Partner reserves the right, in its sole discretion, to waive the minimum dollar amount. |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Blackstone Life Sciences VI - BL LP | [2026-03-30] | 3,615.3 M | 88.2 M |
| Filed 2025-11-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences VI - B LP | [2026-03-30] | 3,615.3 M | 163.0 M |
| Filed 2025-11-20 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences VI LP | [2025-03-28] | 3,615.3 M | 3,762.6 M |
| Filed 2025-12-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $22,925,000 · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences VI Lux SCSP | [2025-03-28] | 3,615.3 M | 372.8 M |
| Filed 2025-12-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Blackstone Life Sciences Yield LP | [2022-03-31] | 1,642.4 M | 376.5 M |
| Offered $1,642,407,000 · Filed 2022-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Blackstone Life Sciences Yield NT LP | [2022-03-31] | 1,642.4 M | 859.4 M |
| Offered $1,642,407,000 · Filed 2022-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Blackstone Life Sciences Yield T LP | [2022-03-31] | 1,642.4 M | 383.2 M |
| Offered $1,642,407,000 · Filed 2022-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences V LP | [2020-01-30] | 4,605.0 M | 6,592.9 M |
| Offered $4,605,000,000 · Filed 2020-07-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Commission $18,161,065 · Revenue Decline to Disclose | ||||
| PE | Blackstone Life Sciences V Lux SCSP | [2020-01-30] | 4,605.0 M | 587.4 M |
| Offered $4,605,000,000 · Filed 2020-07-09 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration One year or less · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 11 | 13.2 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 11 | 13.2 |
| By Discretionary | ||
| Discretionary | 11 | 13.2 |
| Non-Discretionary | 0 | 0.0 |
| Total | 11 | 13.2 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.2 | |
| United States Persons | 11.0 | |
| Total | 11 | 13.2 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| John Finley | Executive Officer | 283 | 16 | |
| Christopher Striano | Executive Officer | 234 | 13 | |
| Matthew Skurbe | Executive Officer | 146 | 13 | |
| Eric Liaw | Executive Officer | 110 | 9 | |
| Omar Rehman | Executive Officer | 153 | 7 | |
| Christopher Placca | Executive Officer | 63 | 6 | |
| Joseph Baratta | Executive Officer | 117 | 5 | |
| Nentcho Nentchev | Executive Officer | 71 | 5 | |
| Tabea Hsi | Executive Officer | 9 | 5 | |
| Nicholas Galakatos | Executive Officer | 53 | 3 | |
| View All | ||||
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| LEI | 9845005B5BIB1AB71B18 |
| Related Firms | State | AUM |
|---|---|---|
|
Blackstone Life Sciences Advisors LLC
✚
|
MA | 13.19 B |
|
Clarus Ventures LLC
✚
|
MA | 805.6 M |
| Comparable Firms | State | AUM |
|---|---|---|
|
JMI Management LP
✚
|
MD | 13.58 B |
|
ArcLight Capital Partners LLC
✚
|
MA | 13.54 B |
|
Partners Enterprise Capital LLC
✚
|
IL | 13.48 B |
|
STG Partners LLC
✚
|
CA | 13.43 B |
|
Eight Partners VC LLC
✚
|
TX | 13.38 B |
|
PCP Managers LP
✚
|
CA | 13.35 B |
|
Asia Alternatives Management LLC
✚
|
CA | 13.24 B |
|
Novacap Management Inc
✚
|
13.17 B | |
|
EMG Fund II Management LP
✚
|
TX | 13.07 B |
|
Impresa Management LLC
✚
|
MA | 13.04 B |